Close Menu
Hormone InsightHormone Insight
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Hormone InsightHormone Insight
    • Home
    • About
    • Trial Guides
    • Diabetes
      • Type 2 Diabetes
      • Diabetes — Trial Guide
      • Type 1 Diabetes
      • Diabetes Prevention
      • Glycaemic Control
      • Complications
      • Technology & Monitoring
    • Endocrinology
      • Thyroid
      • Endocrinology — Topic Guide
      • Adrenal & Pituitary
      • Reproductive Endocrinology
      • Bone & Mineral
    • Metabolism
      • Obesity & Weight
      • Metabolism — Trial Guide
      • Metabolic Syndrome & IR
      • MASLD / Fatty Liver
      • Nutrition & Lifestyle
    • Cardiovascular
      • Cardiovascular Outcomes
      • Cardiovascular — Trial Guide
      • Heart Failure & Renal
      • Lipids & Statins
      • Hypertension
    • Therapeutics
      • GLP-1 Receptor Agonists
      • GLP-1 — Trial Guide
      • SGLT2 Inhibitors
      • SGLT2 — Trial Guide
      • Semaglutide
      • Tirzepatide
      • Liraglutide
    • Clinical Summaries
    • PICO
    • Podcast
    • Categories
    • Contact
    Hormone InsightHormone Insight

    CLINICAL SUMMARIES

    All

    Doctor’s Diary, Entry 7: The Man Who Did Not Believe In His Medication

    By Hormone Insight Editorial TeamJune 28, 20260
    All

    Doctor’s Diary, Entry 6: The Fellow’s First Day

    By Hormone Insight Editorial TeamJune 21, 20260
    All

    CARDS: Atorvastatin Reduces Cardiovascular Events by 37% and Stroke by 48% in Type 2 Diabetes Regardless of LDL Level

    By Hormone Insight Editorial TeamJune 7, 20260
    All

    Heart Protection Study: Simvastatin Reduces Vascular Events by 24% in All High-Risk Patients Regardless of Baseline LDL

    By Hormone Insight Editorial TeamJune 7, 20260
    All

    WOSCOPS: Pravastatin Reduces Coronary Events by 31% in Primary Prevention — Establishing Statins Beyond Secondary Care

    By Hormone Insight Editorial TeamJune 7, 20260
    All

    4S: Simvastatin Reduces Mortality by 30% and Coronary Death by 42% in Established Coronary Heart Disease

    By Hormone Insight Editorial TeamJune 7, 20260

    Recent Obesity article

    Categories

    Laroprovstat Phase 1: LDL Lowering on Rosuvastatin, With Limited Safety Follow-Up

    October 2, 2026 No Comments
    Read More »

    SUSTAIN

    LEARN MORE

    RECENT

    All

    Doctor’s Diary, Entry 7: The Man Who Did Not Believe In His Medication

    By Hormone Insight Editorial TeamJune 28, 20260

    A man who has been on the same small pill for nine years arrives to tell me he does not believe in it. A woman on three medications asks if she can stop the small one. Two composite vignettes from one fictional clinic morning.

    Doctor’s Diary, Entry 6: The Fellow’s First Day

    June 21, 2026

    CARDS: Atorvastatin Reduces Cardiovascular Events by 37% and Stroke by 48% in Type 2 Diabetes Regardless of LDL Level

    June 7, 2026

    Heart Protection Study: Simvastatin Reduces Vascular Events by 24% in All High-Risk Patients Regardless of Baseline LDL

    June 7, 2026

    Liragluitde

    SURMOUNT-1: Tirzepatide Achieves up to 20.9% Weight Loss in Obesity — Entering Surgical Territory

    By Hormone Insight Editorial TeamMarch 24, 2026

    LEADER: Liraglutide Reduces Cardiovascular Death and MACE in High-Risk Type 2 Diabetes

    Liraglutide’s Efficacy in Children Aged 6-12

    Semaglutide Shows vs Liraglutide in Obesity Study

    Daily Semaglutide Shows Superior Blood Sugar Control and Weight Loss Over Liraglutide in Type 2 Diabetes Study

    Subscribe now

    Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

    CATEGORIES

    • Semaglutide
    • Obesity
    • Tirzepatide
    • Liraglutide

    CONTACT INFO

    Contact Us
    Facebook WhatsApp TikTok Instagram

    © 2024-2026 Hormone Insight. All rights reserved.

    • Privacy Policy
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.